The Implication of Autoantibodies in Early Diagnosis and Monitoring of Plasmonic Photothermal Therapy in the Treatment of Feline Mammary Carcinoma

Abstract

Plasmonic Photothermal Therapy (PPTT) is consider an effective localized treatment for pet’s mammary carcinoma with a systemic effect. Its systemic effect has not investigated yet and need many studies to hypothesis how the PPTT eradicate tumor cells. In this study, for the first time, we detected (P53, PCNA, MUC-1, and C-MYC) autoantibodies (AAbs) in feline, studied the relationship between PCNA AAbs and mammary tumors, and investigated the effect of PPTT on humoral immune response of cats with mammary carcinoma through detection of AAbs level before, during, and after the treatment. Firstly, a panel of four AAbs (P53, PCNA, MUC-1, and C-MYC) was evaluated in serum of normal cats and cats clinically diagnosed with mammary tumors using Enzyme-Linked Immunosorbent Assay (ELISA). The panel showed 100% specificity and 93.7% sensitivity to mammary tumors (p > 0.05). Secondary, the panel was evaluated in PPTT monotherapy, mastectomy monotherapy, and combination therapy. PPTT monotherapy decreased AAbs level significantly (p > 0.05) while mastectomy monotherapy and combination therapy had no significant effect (p < 0.05) on AAbs level. The cats treated with PPTT monotherapy showed high survival rate (530 ± 0.0 d; n = 9; 67% censored).